Cargando…

Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2

Currently, SARS-CoV-2, especially the Omicron strain, is ravaging the world and even co-infecting human beings with IAV, which is a serious threat to human public health. As of yet, no specific antiviral drug has been discovered for SARS-CoV-2. This requires deeper understandings of the molecular me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Na, Zhang, Baoge, Deng, Lulu, Liang, Bing, Ping, Jihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132403/ https://www.ncbi.nlm.nih.gov/pubmed/35476817 http://dx.doi.org/10.1080/22221751.2022.2071175

Ejemplares similares

The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
por: Yu, Haiyun, et al.
Publicado: (2023)

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
por: Hu, Yanmei, et al.
Publicado: (2021)

The ecology of viruses in urban rodents with a focus on SARS-CoV-2
por: Fisher, Adam M., et al.
Publicado: (2023)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis
por: Sanhueza, María E., et al.
Publicado: (2023)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
por: Liang, Huang, et al.
Publicado: (2022)

Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry
por: Wu, Wenjiao, et al.
Publicado: (2015)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants
por: Zhao, Hanjun, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants
por: Pérez-Vargas, Jimena, et al.
Publicado: (2023)

Susceptibility of rabbits to SARS-CoV-2
por: Mykytyn, Anna Z., et al.
Publicado: (2021)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
por: Liang, Ziteng, et al.
Publicado: (2023)

A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon
por: Li, Na, et al.
Publicado: (2022)

Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels
por: Zhang, Xiaoxu, et al.
Publicado: (2022)

RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant
por: Yang, Jianing, et al.
Publicado: (2022)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients: SARS-CoV-2 infection impairs islet function
por: Ji, Ningfei, et al.
Publicado: (2022)

SARS-CoV-2 reinfection and COVID-19 severity
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

3D Ex vivo tissue platforms to investigate the early phases of influenza a virus- and SARS-CoV-2-induced respiratory diseases
por: Schloer, Sebastian, et al.
Publicado: (2022)

Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
por: Huang, Qingrui, et al.
Publicado: (2022)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients
por: Lyoo, Kwang-Soo, et al.
Publicado: (2022)

The interaction between NOLC1 and IAV NS1 protein promotes host cell apoptosis and reduces virus replication
por: Zhu, Chunyu, et al.
Publicado: (2017)

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice
por: Huang, Qing, et al.
Publicado: (2023)

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
por: Wang, Miao, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro
por: Mao, Binli, et al.
Publicado: (2022)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
por: Wang, Haomeng, et al.
Publicado: (2022)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

A second functional furin site in the SARS-CoV-2 spike protein
por: Zhang, Yue, et al.
Publicado: (2022)

Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022
por: Solastie, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m93e8lds79rgjvsus8j0uugat9